Skip to main content

Table 1 Characteristics of the patients of the three sets (n = 60)

From: Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia

Patient Sex Age at diagnosis (years) WBC (Count × 109/l) Recurrent Rearrangement Risk group
Set A      
1 F 5 83.1 none HR
2 F 7 21.6 none SR
3 M 2.5 4.5 TEL/AML1 SR
4 F 1.5 1.2 none SR
5 M 4 18.5 TEL/AML1 SR
6 F 2.5 52.5 none HR
7 F 2 5.4 none SR
8 F 8 0.9 none SR
9 M 3 7.8 none SR
10 M 3 5.4 none SR
11 F 2 7.2 none SR
12 F 6 18.4 TEL/AML1 SR
13 F 4 24.3 TEL/AML1 SR
14 F 5 4.5 none SR
15 M 13 3.9 none HR
16 F 2 3.6 none SR
17 M 4 47 TEL/AML1 SR
18 M 10 35.8 TEL/AML1 HR
19 F 3 14.9 none SR
20 F 14 82 none HR
21 M 6 68 none HR
22 F 10 150 none HR
23 M 2 15.4 TEL/AML1 SR
24 M 3 2.9 none SR
25 M 3 5.4 none SR
26 F 3 41 none SR
Set B      
27 F 7.5 4 none SR
28 M 6 26.2 none SR
29 M 15 4.2 none HR
30 F 2 2.2 none SR
31 F 3 22.6 none SR
32 M 2 130 TEL/AML1 HR
33 M 2.5 1.3 TEL/AML1 SR
Set C      
34 F 9 1.4 none SR
35 M 5 12.1 TEL/AML1 SR
36 M 1 34.3 none SR
37 F 6 17.9 none SR
38 M 3 3.3 none SR
39 F 3 7.3 none SR
40 F 6 1.9 TEL/AML1 SR
41 F 6 37.5 TEL/AML1 SR
42 M 5 4.2 none SR
43 F 6 38.7 TEL/AML1 SR
44 F 6 2.7 none SR
45 F 3 13 none SR
46 M 5 1.3 none SR
47 M 3 16.5 TEL/AML1 SR
48 M 3 6.8 TEL/AML1 SR
49 F 5 9.8 none SR
50 M 1 6.8 none SR
51 M 7 36.9 none SR
52 M 2 1.6 none SR
53 M 7 13.5 TEL/AML1 SR
54 M 9 24 none SR
55 F 3 10.2 none SR
56 F 6 9.3 none SR
57 M 3 6.9 none SR
58 M 10 96 none HR
59 M 6 1.4 none SR
60 M 3.5 83.6 none HR
  1. WBC: white blood cell count; F:Female, M:Male
  2. HR and SR are respectively high risk and standard risk groups according to the FRALLE 2000 trial.
  3. • HR: age ≥ 10 years, or white blood cell count ≥ 50 × 109/l, or central nervous system involvement, or t(9;22), or t(4;11) or MLL rearrangement, or hypoploidy (≤ 44 chromosomes)
  4. • SR: 1 ≤ age < 10 years, and white blood cell count < 50 × 109/l, and no central nervous system involvement, and none of the following cytogenetic features: t(9;22), t(4,11) or MLL rearrangement, hypoploïdy
  5. TEL/AML1-positive ALL and TEL/AML1-negative ALL can be assigned to HR or SR categories, according to clinical features.